Tecan initiates succession process for the Board of Directors
(Thomson Reuters ONE) -
Tecan Group AG /
Tecan initiates succession process for the Board of Directors
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Männedorf, Switzerland, October 6, 2017 - The Tecan Group (SIX Swiss Exchange:
TECN) announced today that a succession process for the Board of Directors has
been initiated. Rolf Classon, born in 1945 and member of the Board and Chairman
since 2009, and Gérard Vaillant, born in 1942 and member of the Board since
2004, will not stand for re-election at the ordinary Annual General Meeting on
April 17, 2018. Dr. Lukas Braunschweiler and Dr. Daniel R. Marshak will be
proposed for election as new members. As the successor of Rolf Classon, Dr.
Lukas Braunschweiler will be proposed for election as Chairman of the Board of
Directors.
Over the past few years, Tecan has undergone a process of positive development
enjoying profitable growth above market average. Under the tenure of Dr. David
Martyr, CEO since 2012, and a strengthened leadership team, Tecan has brought to
market a number of new major instrument platforms. It has also increased
recurrent revenues from consumables, today already contributing over 40% of
total sales. Geographical expansion has been strongly pushed forward, with a
particular focus on China. The core business was further strengthened through
four company acquisitions and the divestment of a non-strategic business
segment. Under the tenure of Rolf Classon as Chairman, Corporate Governance has
also been strengthened by removing the registration and voting limitations in
place, thereby making the Tecan share more attractive.
Rolf Classon commented: "Today Tecan is in solid shape and the foundations have
been laid for many more years of strong development. Therefore, this is a good
point in time to initiate a succession process for the Board of Directors. I am
very happy that, with Lukas Braunschweiler and Daniel R. Marshak, two highly
successful and experienced leaders will be proposed for election. I take the
chance to wholeheartedly thank Gérard Vaillant for his contribution over many
years as member of the Board and in his role as acting CEO in 2012."
Two new members will be proposed
Dr. Lukas Braunschweiler, born in 1956, is CEO of Sonova Holding AG (SIX Swiss
Exchange: SOON) since 2011 and will remain in his role until end of March 2018.
He has already been a member of the Board of Directors of the Tecan Group and
Chairman of the Audit Committee, from 2009 until 2012. Before his role at
Sonova, he was with RUAG Holding AG as CEO. He previously was a Delegate of the
Board of Directors and CEO of Dionex Corporation, a US-based manufacturer of
laboratory instruments (today part of Thermo Fisher Scientific Inc.). He also
held executive positions at a number of major high-tech companies including
Mettler-Toledo and Landis & Gyr. Lukas Braunschweiler graduated from the Swiss
Federal Institute of Technology (ETH Zurich) in physical chemistry and is a
Swiss citizen. He currently serves as a member of the Board of Directors of
Schweiter Technologies AG (SIX Swiss Exchange: SWTQ). In addition, the Board of
Directors of Sonova has announced to propose Lukas Braunschweiler for election
as a member of the Board of Directors of Sonova at its Annual General Meeting in
June 2018.
Dr. Daniel R. Marshak, born in 1957, is an experienced executive in the life
sciences, diagnostics and biopharmaceuticals industries, leading high
technology, global businesses and R&D functions for more than 20 years. From
2006 to 2014 he worked at PerkinElmer, Inc. (NYSE: PKI). In his last role as
Senior Vice President and Chief Scientific Officer, he was responsible for all
science and technology as well as research and development activities and also
led several acquisitions during that time. Before joining PerkinElmer, Daniel R.
Marshak was Vice President and Chief Technology Officer, Biotechnology, at
Cambrex Corporation (NYSE: CBM) and Senior Vice President and Chief Scientific
Officer at Osiris Therapeutics, Inc. (OTC: OSIR). Prior to his corporate career,
he held various research positions in academia and research institutions, such
as Adjunct Associate Professor at The Johns Hopkins University, School of
Medicine, Senior Staff Investigator at Cold Spring Harbor Laboratory, and
Assistant Professor, School of Medicine at State University of New York at Stony
Brook. Daniel R. Marshak studied Biochemistry at Harvard University and holds a
Ph.D. in Biochemistry & Cell Biology from The Rockefeller University in New
York. He is a US citizen and currently serves as a member of the Board of
Directors of InVivo Therapeutics Holdings Corporation (NASDAQ: NVIV) and
privately held Upside Biotechnologies, Ltd. in Auckland, New Zealand.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and
solutions in biopharmaceuticals, forensics and clinical diagnostics. The company
specializes in the development, production and distribution of automated
workflow solutions for laboratories in the life sciences sector. Its clients
include pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original equipment
manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales and
service network in 52 countries. In 2016, Tecan generated sales of CHF 506
million (USD 511 million; EUR 464 million). Registered shares of Tecan Group are
traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Tecan Group
Martin Braendle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor(at)tecan.com
www.tecan.com
Press Release:
http://hugin.info/100384/R/2140199/819498.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Tecan Group AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.10.2017 - 17:45 Uhr
Sprache: Deutsch
News-ID 562769
Anzahl Zeichen: 7046
contact information:
Town:
Maennedorf
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 301 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Tecan initiates succession process for the Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Tecan Group AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
